BioXcel Therapeutics, Inc. (BTAIQ) Financials
Annual revenue, profitability and per-share results for BioXcel Therapeutics, Inc., as reported in SEC filings.
Revenue • FY2025
$642K
▼ 71.7%YoY
Net income • FY2025
-$69.9M
▼ 17.3%YoY
Gross margin • FY2025
74.5%
Diluted EPS • FY2025
-$5.73
▲ 75.6%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $642K | -$69.9M | $478K | -$5.73 | -$57.62M | -7860.0% | -71.7% |
| FY2024 | $2.27M | -$59.6M | $123K | -$23.51 | — | -2967.6% | +64.2% |
| FY2023 | $1.38M | -$179.05M | $120K | -$6.15 | -$155.03M | -12448.0% | +268.0% |
| FY2022 | $375K | -$165.76M | $355K | -$5.92 | -$135.48M | -42572.0% | — |
Figures as reported in BioXcel Therapeutics, Inc.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a BTAIQ filing.
Get an email when BTAIQ files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.